AxoGen, Inc. Announces Closing Of Public Offering Of Common Stock

ALACHUA, Fla., May 14, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (Nasdaq:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced the closing of its previously announced underwritten public offering of 3,450,000 shares of its common stock, at a price to the public of $41.00 per share. The number of shares sold by AxoGen includes an aggregate of 450,000 shares of common stock offered and sold pursuant to an option granted to the underwriters that was exercised in full. The total net proceeds from the offering for AxoGen are estimated to be approximately $132,463,000, after deducting underwriting discounts and commissions and other estimated offering expenses payable by AxoGen. AxoGen intends to use the net proceeds from the offering for long term facility and capacity expansion and general corporate purposes.

Jefferies LLC and Leerink Partners LLC acted as joint book-running managers for the offering. William Blair & Company, L.L.C and JMP Securities LLC acted as co-managers.

The offering was made pursuant to a shelf registration statement on Form S-3 that AxoGen filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 7, 2018 and that became effective upon filing. A final prospectus supplement describing the terms of the offering has been filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectuses relating to the offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by email at, or by telephone at 877-821-7388 and Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, by email at, or by telephone at (800) 808-7525, ext. 6132.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

1 2 3
View single page >> |

Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from sources and ...

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.